Kornimate/medical-research-clean huggingface dataset:
immunotherapy of hepatocellular carcinoma by induction of anti-alpha fetoprotein response

Conditions: Hepatocellular Carcinoma

Summary: the secretion by tumor cells of alpha fetoprotein (afp) was observed in 50 to 60% of hepatocellular carcinoma. the afp can be used as a marker for tumor recurrence after treatment and may be considered as a tumor antigen specific for hepatocellular carcinoma.the aim of the project is to use the alpha fetoprotein (afp) as a tumor antigen and to propose an approach of immunotherapy for hepatocellular carcinoma based on the injection of autologous dendritic cells loaded with specific peptides of afp.


Eligibility criteria:
pre-inclusion criteria : * adults (men or women) aged between 18 and 80 years * patients affiliated to a social security reimbursement system * signed informed consent * hepatocellular carcinoma * at least one dosage with alpha-foeto-protein ≥ 40 ng/ml * patient already treated with chemoembolization, percutaneous destruction (alcohol or radiofrequency), surgery or sorafenib. inclusion criteria: * negative test for pregnancy or effective contraception * patient hiv-, hep b-, hep c-, htlv1 and 2-, syphilis- * hla a 0201 group exclusion criteria: * life expectancy \< 3 months * pregnancy or breast-feeding * severe auto-immune disease * another malignant tumor except if considered as cured since more than 5 years * history of uncontrolled psychiatric condition * risk factors of creutzfeldt jacobs disease * decompensated cirrhosis(ascites or child-pugh score greater than 8) * hepatic transplantation

Keywords: hepatocellular carcinoma immunotherapy alpha foetoprotein dendritic cells
fetoscopic open spina bifida repair using the safer technique

Conditions: Open Spina Bifida; Myelomeningocele; Meningomyelocele; Chiari Malformation With Spina Bifida; Chiari Malformation Type 2

Summary: children submitted to fetoscopic in utero myelomeningocele repair using the safer (skin-over-biocellulose for anternatal fetoscopic repair) technique will evaluate at 30 months or more, regarding ambulation, neurodevelopment, urinary and fecal status.

children submitted to fetoscopic in utero myelomeningocele repair using the safer (skin-over-biocellulose for anternatal fetoscopic repair) technique will evaluate the neuropsicomotor development at 30 months of chronological age. the mental evaluation will use the bayley iii and thepedi neurodevelopmental scale. the motor development will use the difference between anatomic and motor level of the lesion. urinary and fecal continence will be evaluated using clinical and ultrasonographic parameters. for the anatomical level determination, immaging of the spine at the lesion level will be used. motor level and ambulation will be evaluated through standard clinical examination.

Eligibility criteria:
inclusion criteria: children operated in utero using the safer technique exclusion criteria: death before 30 month

Keywords: myelomeningocele spina bifida meningomyelocele fetal surgery fetoscopy fetal disease fetal treatment
a study of cc-95251, a monoclonal antibody directed against sirpα, in participants with advanced solid and hematologic cancers

Conditions: Neoplasms

Summary: the purpose of this study is to evaluate the safety, tolerability, and preliminary clinical activity of cc-95251 as a single agent and in combination with cetuximab and rituximab in participants with advanced solid and hematologic cancers.

this is a test.

Eligibility criteria:
inclusion criteria: * progressed on standard anticancer therapy or for whom no other approved conventional therapy exists and have histological or cytological confirmation of advanced unresectable solid tumors, advanced unresectable colorectal cancer, or squamous cell carcinoma of the head and neck, or cd20-positive non-hodgkin's lymphoma, or diffuse large b cell lymphoma, or follicular lymphoma * solid tumors must have at least one site of measurable disease as determined by recist v1.1 * eastern cooperative oncology group performance status of 0 or 1 exclusion criteria: * high-grade lymphomas (burkitt's or lymphoblastic) * has cancer with symptomatic central nervous system (cns) involvement * history of class iii or iv congestive heart failure (chf) or severe non-ischemic cardiomyopathy, unstable angina, myocardial infarction, or ventricular arrhythmia within the previous 6 months other protocol-defined inclusion/exclusion criteria apply

Keywords: antibody cc-95251 sirpα advanced solid cancers advanced hematologic cancers
disseminating and implementing a smoking cessation program for pregnant and postpartum women

Conditions: Smoking; Tobacco Use Disorder

Summary: this study tests whether a smoking cessation intervention for pregnant women that extends postpartum (striving to quit (stq)) can be implemented and disseminated outside of the research environment that established its effectiveness (40% maintained biochemically verified 6-month abstinence). the research aim is: is striving to quit more effective in achieving postpartum smoking cessation than "first breath," the current standard of care for pregnant women in wisconsin who smoke? 250 women will be randomized into one of two study groups. pregnant women in group a (n=125) will receive the existing first breath prenatal intervention. those in group b (striving to quit (stq), n=125) will receive all group a interventions, plus 1 additional prenatal home visit, 3 postpartum in-home smoking cessation counseling visits, 3 postpartum phone calls, and up to an additional $100 in gift cards. the primary outcome will be biochemically confirmed smoking cessation at 6-months postpartum.


Eligibility criteria:
inclusion criteria: * pregnant; * enrolled in first breath; * resides in wisconsin counties of calumet, fond du lac, kewaunee, menominee, oconto, shawno, sheyboygan, winnebago, door, brown, outagamie, manitowac, or waupaca; * english speaking; * willingness to quit or reduce smoking in next 30 days or if already quit, desire to remain quit after delivery; * daily smoking (at least 1 cigarette/day for at least 1 week in past 6 months; * willing to provide updates in contact information exclusion criteria: * not pregnant; * not smoking in past 6 months; * involved in another smoking research study.
efficacy of lactose-free milk in treating acute gastroenteritis in infants

Conditions: Acute Gastroenteritis

Summary: the purpose of this study is to determine whether lactose-free milk will change diarrhea duration and severity in formula-fed infants with acute gastroenteritis presenting to pediatric wards.

more than 525 000 children die each year due to diarrheal disease, the second leading cause of death among children under five. children from asian countries, including vietnamese children, frequently have lactose intolerance. in addition, gastroenteritis, specifically rotavirus-induced gastroenteritis, temporarily impairs lactase enzymes in the intestines. in a recent cochrane review of 33 randomized and quasi-randomized trials, lactose-free diets reduced diarrhea among children younger than 5 years old. these trials, however, involved inpatients in middle-or high-income countries. neither patient was from a developing country, where diarrheal diseases often cause significant morbidity and mortality. the purpose of this study is to determine whether lactose-free milk will change the duration and severity of diarrhea in vietnamese infants with acute gastroenteritis.

Eligibility criteria:
inclusion criteria: * children 2- 24 months old on artificial milk formula * acute diarrhea (3 or more loose or liquid stools per day) exclusion criteria: * used antibiotics within 3 days before admission * breastfeeding * severe dehydration, defined by a need of iv rehydration * malnutrition (weight/height\< -3sd) * chronic underlying disease, immunocompromised condition or systemic infection

Keywords: diarrhea lactose-free diet
interdisciplinary medication review interventions in an integrated outpatient department.

Conditions: Comorbidity; Multimorbidity; Drug Prescribing; Cognitive Impairment; Language Problems

Summary: inappropriate medication prescribing is highly prevalent among comorbid medical patients and leading to adverse drug events (ade), re-admissions, quality of life and mortality. thus, the aim of this study is primary to investigate the feasibility of a interdisciplinary intervention focused on deprescribing and medication optimization in the integrated outpatient department at copenhagen university hospital, amager, denmark. participants in the intervention group receives a medication review by a clinical pharmacist and physician with a follow up after 7 and 30 days. the control group receives standard care.

the fma-cph trial is designed as a single-blinded randomized controlled pilot trial starting at the first consultation and end 30 days after. patients that meet all inclusion criteria and none of the exclusion criteria are invited to participate. after signing a written informed consent, the participants are block randomized to either the intervention or control group. medication prescription for comorbid patients is challenging and may be attributed to marked inter-individual variations in general health, organ function, pharmacokinetic and pharmacodynamic properties, biological age and physical performance. the intervention group receive a medication review. it is hypothesized that the intervention is feasible and more patients in the intervention group will complete ≥1 deprescribing and/or ≥1 medication optimization 30 days after the beginning of the intervention than the patients in the control group. secondary it is hypothesized the patients in the intervention group: a. complete more deprescribing compared to the control group (30 days after intervention) b. complete more medication optimization compared to the control group (30 days after intervention) c. have a higher knowledge about own medication (14 days after intervention) d. have a higher level of satisfaction with medication information (14 days after intervention)

Eligibility criteria:
inclusion criteria: * consultation at integrated outpatient department subacute track * multi morbidity/comorbidity * drug prescribing * mentally fresh * understand and speak danish exclusion criteria: * unable to cooperate cognitively * language problems * admission

Keywords: deprescibing multimorbidity/comorbidity knowledge interdiciplinary intervention medication information motivation
safety and efficacy of saf312 in patients with neurogenic detrusor overactivity due to spinal cord lesions

Conditions: Neurogenic Urinary Bladder; Neurogenic Bladder Disorder; Neurogenic Dysfunction of the Urinary Bladder; Neurogenic Bladder, Uninhibited; Neurogenic Bladder, Spastic

Summary: this study will assess the safety, tolerability and efficacy of saf312 in patients with overactive bladder disease due to spinal cord lesions. the overactive bladder of patients who qualify for this study is insufficiently managed by antimuscarinic therapy, or patients poorly tolerate the treatment with antimuscarinic drugs. the efficacy of saf312 will be primarily determined via urodynamic measurements.


Eligibility criteria:
inclusion criteria: * patients with neurogenic detrusor overactivity due to spinal cord lesions * patients are inadequately managed by antimuscarinic medication and present with a cystometric bladder capacity of max. 400 ml exclusion criteria: * chronic inflammation such as interstitial cystitis, bladder stones, hematuria of unknown origin, previous pelvic radiation therapy or previous or current malignant disease of the pelvic organs * pelvic or genitourinary tract anomalies including surgery or bladder disease other than detrusor overactivity impacting on bladder function

Keywords: neurogenic detrusor overactivity spinal cord lesions spinal cord injury
effect of beta blocker treatment on endothelial function in patients with type 2 diabetes or chronic heart failure

Conditions: Endothelial Function; Beta Blocker

Summary: the aim of this study is to evaluate the effect of the two different beta blockers metoprolol and carvedilol on endothelial function in patients with either type two diabetes or chronic heart failure. hypothesis: 1\* carvedilol compared to metoprolol has a favourable effect on endothelial function. 2\* carvedilol compared to metoprolol has a favourable effect on insulin stimulated endothelial function. the study is conducted as an open parallel group study. endothelial function and insulin stimulated endothelial function was evaluated before and after a two months treatment period with either of the two beta blockers.

endothelial function is deteriorated in patients with type 2 diabetes and in patients with chronic heart failure. treatment with carvedilol improves survival in patients with chronic heart failure compared to treatment with metoprolol. carvedilol improves metabolic glucose control in patients with diabetes compared to metoprolol.carvedilol compared to metoprolol also decreases the number of patients with new onset diabetes among patients with chronic heart failure. the mechanism behind these findings has not been fully understood. the purpose of this study is to investigate if carvedilol compared to metoprolol has a favourable effect on endothelial function and insulin stimulated endothelial function, in groups of patients with either diabetes or chronic heart failure.

Eligibility criteria:
inclusion criteria: * type 2 diabetes * chronic heart failure exclusion criteria: * for patients with type 2 diabetes: \* vascular complications. * for patients with chronic heart failure: * severe uncontrolled heart failure. * untreated severe hypertension, hypotension. * bradycardia. * known intolerance to beta blocker treatment. * pregnancy,

Keywords: endothelial function beta blocker type 2 diabetes chronic heart failure
lactobacillus reuteri for non-surgical periodontal treatment of chronic periodontitis with type 2 diabetes patients

Conditions: Periodontitis

Summary: this study aims to investigate the clinical and microbiological efficacy of lactobacillus reuteri as an adjunctive therapy to non-surgical periodontal treatment of chronic periodontitis with type 2 diabetes.

periodontitis and diabetes affect the course and outcome of each other. many studies have shown that for patients with periodontitis, concomitant diabetes can aggravate the destruction of periodontal tissue and accelerate the progression of periodontitis, which is an important risk factor for periodontitis. affected by diabetes, patients with poor glycemic control have worse periodontal status, and the prognosis of periodontitis treatment is more suspicious. conversely, periodontitis also affects diabetic status, and periodontitis is associated with dysglycemia, increased insulin resistance, and increased risk of diabetic complications. after periodontal therapy, it is expected to reduce the level of systemic inflammation and ultimately improve glycemic control and overall prognosis of diabetes. however, the treatment of periodontitis with diabetes is still a challenge, and how to improve the prognosis of patients with periodontitis with type 2 diabetes remains to be studied. biogaia prodentis is a probiotic chewable tablet containing lactobacillus reuteri (combination of l. reuteri dsm 17938 and l. reuteri atcc 5289). studies have shown that the use of the probiotics has an additional effect on periodontal therapy. however, in the periodontitis patients with type 2 diabetes, whether the use of this probiotic can improve the effect of periodontal therapy, few relevant research have published.

Eligibility criteria:
inclusion criteria: 1. age between 35 to 70 years, 2. type 2 diabetes with treatment ≥ 6-month, with hba1c≤7.5%, 3. generalized periodontitis (stage iii or iv), 4. no less than 15 teeth exclusion criteria: 1. smoking, or quit smoking for less than 5 years; 2. suffering from other known systemic diseases that can affect the progression of periodontitis (immune abnormalities, osteoporosis, history of head and neck radiotherapy, etc.); 3. received periodontal treatment within 6 months; 4. have taken antibiotics, non-steroidal anti-inflammatory drugs, immunosuppressants, hormones and other drugs that affect periodontal within 3 months; 5. have taken probiotics within 6 months; 6. prophylactic use of antibiotics is required; 7. pregnant and lactating women;
the effect of nurse-led body protection education in students with visual impairments

Conditions: Child Sexual Abuse; Disability, Vision

Summary: in the study, it was aimed to examine the effect of nurse-led body protection education on the sexual abuse knowledge levels of students with visual impairments.

children with visual impairments form a risky group in terms of abuse as they are more dependent in relation to providing self-care compared to children with visually healthy and they use their sense of touch in communicating with the environment. the 53 students with visual impairments were randomly assigned to the intervention group and the control group. the study data were collected through children's knowledge of abuse questionnaire - revised with the subdimensions of good touch and bad touch. nurse-led body protection education was provided to the intervention group in groups of 3-4 in 40 minutes. the education was provided as verbal narration by using a doll and distress whistle. in addition, two weeks after the post-test, a reminder education brochure prepared with the braille alphabet was distributed to the students in the intervention group.

Eligibility criteria:
inclusion criteria: * students with visual impairments who gave their consent to participate in the study and who could communicate in turkish were included in the study. exclusion criteria: * students who had a mental disability in addition to visual impairment were excluded from the study.

Keywords: child sexual abuse visually impaired children prevention health education public health nursing
intrathecal hydromorphone for pain control after cesarean section

Conditions: Pain; Cesarean Section

Summary: the use of intrathecal opioids for analgesia in the setting of cesarean section has become standard obstetric anesthesia practice. currently, two opioids are commonly used. these opioids are fentanyl and morphine (duramorph). intrathecal opioids are an excellent source of analgesia and act to reduce the stress response to surgery. currently, most obstetric anesthesiologists use intrathecal morphine for analgesia after cesarean delivery. morphine provides excellent analgesia for cesarean section. however, use of this medication is associated with side effects such as pruritus and nausea and vomiting. recently, multiple obstetric anesthesia groups began to use intrathecal hydromorphone for cesarean delivery when morphine was unavailable. as groups began to use hydromorphone, retrospective data became available that demonstrated its safety and efficacy for use during cesarean section. in order to fully elucidate the analgesic and side effect properties of hydromorphone for cesarean delivery, a prospective randomized, double blind study comparing morphine and hydromorphone is necessary. the investigators need to understand whether hydromorphone is as effective as morphine for analgesia after cesarean section, and whether it is associated with fewer or more side effects. the results of the study will allow providers to make educated decisions to better care for their patient.


Eligibility criteria:
inclusion criteria: * elective primary cesarean section * females age 18-40 exclusion criteria: * emergency cesarean section * anesthetic other than spinal * history of chronic pain or pre-op opioid use * allergy to morphine or hydromorphone * bmi\>40

Keywords: intrathecal hydromorphone intrathecal morphine primary cesarean section analgesia
effect of a sepsis prediction algorithm on clinical outcomes

Conditions: Severe Sepsis

Summary: in this clinical outcomes analysis, the effect of a machine learning algorithm for severe sepsis prediction on in-hospital mortality, hospital length of stay, and 30-day readmission was evaluated.

materials and methods: clinical outcomes evaluation performed on a multiyear, multicenter clinical data set of real-world data containing 75,147 patient encounters from nine hospitals. mortality, hospital length of stay, and 30-day readmission analysis performed for 17,758 adult patients who met two or more systemic inflammatory response syndrome (sirs) criteria at any point during their stay.

Eligibility criteria:
inclusion criteria: * all patients over the age of 18 presenting to the emergency department or admitted to an inpatient unit at the participating facilities were automatically included for clinical outcomes analysis exclusion criteria: * patients under the age of 18

Keywords: dascena patient mortality length of stay readmissions algorithm diagnostic clinical outcomes
the study of microrna genomics of blood stasis syndrome and of coronary heart disease

Conditions: Coronary Heart Disease; Unstable Angina; Blood Stasis Syndrome

Summary: in this study, typical cases of blood stasis syndrome of coronary heart disease are selected, by using microrna chip, cdna microarray and other bioinformatics technologies to filter and verify related mirna and its target gene of coronary heart disease. meanwhile, intervene by xuesaitong soft capsules to investigate related mirna and its target gene of coronary heart disease.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of coronary angiography unstable angina * clinical diagnosis of unstable angina * age of 30 to 75 years old * not use thrombolysis, dilate coronary drugs within two weeks * tongue dark * sign the consent exclusion criteria: * severe valvular heart disease * insulin-dependent diabetes * mental disease * combined with severe liver, kidney, hematopoietic system disorder * patients with malignant tumors * pregnancy or breast-feeding women * recent history of trauma * drug allergy

Keywords: microrna coronary heart disease unstable angina blood stasis syndrome xuesaitong soft capsule
study evaluating pneumococcal vaccine in healthy infants

Conditions: Healthy Subjects; Pneumococcal Infections

Summary: the purpose of this study is to evaluate the safety and immunogenicity of the 13-valent pneumococcal conjugate vaccine (13vpnc) in healthy infants. this is the first study with this vaccine in infants.


Eligibility criteria:
inclusion criteria: 1. aged 6 weeks to 14 weeks (42-98 days of age) at time of enrollment, 2. in good health as determined by medical history, physical examination and judgment of the investigator, 3. subject must have been born ≥36 weeks of gestational age, 4. subject must be available for entire study period and whose parent/legal guardian can be reached by telephone, 5. parent/legal guardian must be able to understand and sign an informed consent form prior to participation and complete a parent worksheet during study participation. exclusion criteria: 1. previous vaccination with licensed or investigational pneumococcal vaccine, 2. previous vaccination with hib conjugate, dtap or ipv vaccines, 3. contraindication to immunization with hepb, hib conjugate, dtap or ipv vaccines, 4. significant neurological disorder or history of seizure including febrile seizure, or significant stable or evolving disorders such as cerebral palsy, encephalopathy, hydrocephalus or other significant disorders. does not include resolving syndromes due to birth trauma such as erb palsy, 5. bleeding diathesis or condition associated with prolonged bleeding time that would contraindicate intramuscular injection, 6. history of culture-proven invasive disease caused by s. pneumoniae, 7. previous anaphylactic reaction to any vaccine or vaccine components, 8. major known congenital malformation or serious chronic disorders, 9. participation in another investigational study (however, observation-only trials are permitted), 10. known or suspected immune deficiency/suppression, 11. receipt of blood products or gamma globulin (including hepatitis b immunoglobulin and monoclonal antibody; eg, synagis®).

Keywords: infant vaccine